Imizol Injection is a clear, sterile, aqueous solution for the treatment and prevention of Babesiosis in cattle, sheep, horses and dogs, Anaplasmosis in cattle and Ehrlichiosis in dogs.
This page contains information onImizol Injection for veterinary use.
The information provided typically includes the following:
Imizol Injection Indications
Warnings and cautions for Imizol
Direction and dosage information for Imizol Injection
This treatment applies to the following species:
Company of Imizol Injection: Intervet/Merck Animal Health
NADA #141-071, Approved by FDA.
Each mL contains 120 mg of imidocarb dipropionate.
Sterile solution for intramuscular or subcutaneous Imizol Injection
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
Imizol Injection (imidocarb dipropionate) is a sterile solution containing 120 mg/mL of imidocarb dipropionate suitable for intramuscular or subcutaneous administration. Imidocarb is chemically described as N,N’-bis[3-(4,5-dihydro-1H-imidazol-2-yl)-phenyl]urea dipropionate and has a molecular weight of 496.6. In addition to the active component, imidocarb dipropionate, the formulation also contains propionic acid (22.34 mg/mL), and water for injection.
For the treatment of dogs with clinical signs of babesiosis and/or demonstrated Babesia organisms in the blood.
Dosage and Administration
Use intramuscularly or subcutaneously at a rate of 6.6 mg/kg (3 mg/lb) body weight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.
NOT FOR HUMAN USE. KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. IN THE EVENT OF HUMAN EXPOSURE IMMEDIATELY CALL FOR MEDICAL ADVICE FOR HUMANS.
Oncogenesis: Increased incidence of tumors was observed in rats given imidocarb.
MUST NOT BE ADMINISTERED INTRAVENOUSLY. The safety and effectiveness of imidocarb have not been determined in puppies or in breeding, lactating, or pregnant animals. Risk versus benefit should be considered before using this drug in dogs with impaired lung, liver, or kidney function.
Do not use this product simultaneously with exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.
Adverse effects commonly seen are pain during injection and mild cholinergic signs such as salivation, nasal drip, or brief episodes of vomiting. Other effects seen less frequently are panting, restlessness, diarrhea, and mild injection site inflammation lasting one to several days. Rarely, injection site ulceration occurs, but the lesion is not resistant to healing.